Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 3/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.44 |
| ▸ | TACR3 | P29371 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2720873 | 0.72 | MAPK1 (0.38) | — | |
| SCHEMBL22490815 | 0.70 | HDAC1 (0.35) | — | |
| SCHEMBL2030447 | 0.70 | NPSR1 (0.44) | HCAR3HCAR2 | |
| SCHEMBL2363242 | 0.69 | HTT (0.48) | TACR3 | |
| SCHEMBL20790087 | 0.68 | HDAC1 (0.49) | — | |
| SCHEMBL1117966 | 0.68 | HDAC3 (0.41) | — | |
| SCHEMBL19029371 | 0.68 | HDAC6 (0.40) | — | |
| SCHEMBL18662334 | 0.66 | USP2 (0.38) | TACR3 | |
| SCHEMBL16335161 | 0.66 | HDAC3 (0.45) | — | |
| SCHEMBL18662324 | 0.66 | PDE2A (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4349408-A2 | METHODS FOR TREATING PROTEINOPATHIES | Genzyme Corporation (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-3267983-B1 | METHODS FOR TREATING PROTEINOPATHIES | GENZYME CORP (US) | 2023-12-20 | — | — | EP | disclosed |
| EP-4100009-A1 | METHODS FOR TREATING NEUROLOGICAL SYMPTOMS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | Genzyme Corporation (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220110922-A1 | TREATMENT OF CILIOPATHIES USING INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE (GCS) | GENZYME CORPORATION (US) | 2022-04-14 | — | — | US | disclosed |
| US-20220023273-A1 | METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | GENZYME CORPORATION (US) | 2022-01-27 | — | — | US | disclosed |
| US-20220016092-A1 | METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | GENZYME CORPORATION (US) | 2022-01-20 | — | — | US | disclosed |
| EP-3920912-A1 | TREATMENT OF CILIOPATHIES USING INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE (GCS) | Genzyme Corporation (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3920914-A1 | METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | Genzyme Corporation (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3920913-A1 | METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | Genzyme Corporation (US) | 2021-12-15 | — | — | EP | disclosed |
| US-20210251982-A1 | METHODS FOR TREATING NEUROLOGICAL SYMPTOMS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | GENZYME CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20200197374-A1 | METHODS FOR TREATING PROTEINOPATHIES | GENZYME CORPORATION | 2020-06-25 | — | — | US | disclosed |
| US-20200048266-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORP (US) | 2020-02-13 | — | — | US | disclosed |
| US-20180036295-A1 | METHODS FOR TREATING PROTEINOPATHIES | GENZYME CORPORATION | 2018-02-08 | — | — | US | disclosed |
| EP-3267983-A1 | METHODS FOR TREATING PROTEINOPATHIES | Genzyme Corporation (US) | 2018-01-17 | — | — | EP | disclosed |
| WO-2016145046-A1 | METHODS FOR TREATING PROTEINOPATHIES | GENZYME CORPORATION (US) | 2016-09-15 | — | — | WO | disclosed |
| US-20160207933-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION | 2016-07-21 | — | — | US | disclosed |
| US-9139580-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2015-09-22 | — | — | US | disclosed |
| US-20140255381-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2014-09-11 | — | — | US | disclosed |
| EP-2685986-A2 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2014-01-22 | — | — | EP | disclosed |
| WO-2012129084-A2 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2012-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048266-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | HCAR3 1796/4885HCAR2 2070/4885TACR3 4236/4885 |
| US-20200197374-A1 | METHODS FOR TREATING PROTEINOPATHIES | SNCA, PRNP, PARK7 | HCAR3 4446/4885HCAR2 4636/4885TACR3 2194/4885 |
| US-20220016092-A1 | METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | GAA, GBA1, GALC | HCAR3 3520/4885HCAR2 3659/4885TACR3 2899/4885 |
| US-20210251982-A1 | METHODS FOR TREATING NEUROLOGICAL SYMPTOMS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | GBA1, GBA2, CLN6 | HCAR3 2309/4885HCAR2 1861/4885TACR3 1736/4885 |
| US-20220110922-A1 | TREATMENT OF CILIOPATHIES USING INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE (GCS) | GBA1, GBA2, GALC | HCAR3 2874/4885HCAR2 3745/4885TACR3 2623/4885 |
| US-20160207933-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | HCAR3 1797/4885HCAR2 2052/4885TACR3 4215/4885 |
| US-20140255381-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | HCAR3 1797/4885HCAR2 2052/4885TACR3 4215/4885 |
| US-20220023273-A1 | METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | GAA, GBA1, CMA1 | HCAR3 3117/4885HCAR2 3260/4885TACR3 2966/4885 |
| US-20180036295-A1 | METHODS FOR TREATING PROTEINOPATHIES | SNCA, PRNP, PARK7 | HCAR3 4446/4885HCAR2 4636/4885TACR3 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.